AN2 Therapeutics, Inc. (ANTX)

Market Cap	37.92M
Revenue (ttm)	n/a
Net Income (ttm)	-51.32M
Shares Out	30.10M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,429
Open	1.260
Previous Close	1.280
Day's Range	1.240 - 1.280
52-Week Range	0.870 - 3.070
Beta	-0.01
Analysts	Buy
Price Target	3.50 (+180.0%)
Earnings Date	May 13, 2025

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Ph...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX
• Website: https://www.an2therapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 180.00% from the latest price.

Price Target

$3.5

(180.00% upside)

Analyst Consensus: Buy